SYT-510 explained

SYT-510 is an endocannabinoid reuptake inhibitor, or "selective endocannabinoid reuptake inhibitor" ("SERI"), which is under development for the treatment of anxiety disorders, mood disorders, and traumatic stress disorders.^{[1] [2] [3]} It is said to mildly and selectively increase levels of endocannabinoids like anandamide via inhibition of a newly identified biological target.^[4] As of January 2024, the drug is in the preclinical stage of development or is entering phase 1 clinical trials for the preceding indications. It is under development by a pharmaceutical company called Synendos Therapeutics.

External links

• SYT-510 - AdisInsight
• Approach (SYT-510) - Synendos Therapeutics

Notes and References

1. Web site: SYT 510 . AdisInsight . 22 January 2024 . 15 August 2024.
2. Web site: Delving into the Latest Updates on SYT-510 with Synapse . Synapse . 4 August 2024 . 15 August 2024.
3. Gertsch J, Chicca A . CNS Drug Discovery in Academia: Where Basic Research Meets Innovation . ChemBioChem . e202400397 . July 2024 . 38958639 . 10.1002/cbic.202400397 . Five years after incorporation, Synendos Therapeutics has completed non-clinical development of the [selective endocannabinoid reuptake inhibitor (SERI)] drug candidate SYT-510 and has initiated Phase 1 clinical development in healthy volunteers, marking the significant transition into a clinical stage biotech company. The mission of Synendos is to develop breakthrough safe and effective therapies for neurological and neuropsychiatric disorders through modulation of the [endocannabinoid system (ECS)] with SERIs to enable restoration of the natural functioning of the brain..
4. Web site: Therapeutics . Synendos . Synendos Therapeutics AG Granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510 . PR Newswire . 18 January 2024 . 15 August 2024.